Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Allergic rhinitis and asthma
Avamys has targeted action, with high receptor affinity, longer tissue retention and low bioavailability.
Dosing
Prescribe Avamys once daily1
For adults and adolescents from
12 years of age:
2 sprays per nostril once daily1
For children aged 2 to 11 years:
1 spray per nostril once daily1
Download full Prescribing Information for Avamys
A modern delivery system2–4
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/MP4/Avamys/avamys_am_2021_how_to_use_device_video_saudi_augg.mp4
The differences between FFNS and MFNS devices
Video player requires JavaScript enabled. You can download this video here: https://videos.gskinternet.com/pharma/GSKpro/SaudiArabia/MP4/Avamys/avamys_am_2024_device_features_video_saudi.mp4
Read more about Avamys
Abbreviations
AE: adverse event; FF: fluticasone furoate; FFNS: fluticasone furoate nasal spray; FPNS: fluticasone propionate nasal spray; MFNS: mometasone furoate nasal spray.
References
- Avamys local prescribing information based on GDS 11.
- Berger WE, et al. Expert Opin Drug Deliv 2007;4:689–701.
- Godfrey JW, et al. J Allergy Clin lmmunol 2007;119:S230.
- Meltzer EO, et al. Clin Ther 2008;30:271–279.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com
Trade marks are owned by or licensed to the GSK group of companies.
Date of preparation: August 2024. PM-SA-FLF-WCNT-240001
